The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC

Expert Discusses Fractionated Dose 177Lu-PSMA-617 in mCRPC

Scott T. Tagawa, MD, MS
Published Online: 2:37 PM, Fri October 26, 2018


Scott T. Tagawa, MD, MS, Richard A. Stratton Associate Professor in Hematology and Oncology, associate professor of clinical medicine & urology at Weill Cornell Medicine, associate attending physician, NewYork-Presbyterian–Weill Cornell Medical Center, discusses fractionated dose 177Lu-PSMA-617 in metastatic castration-resistant prostate cancer (mCRPC).
 
Investigators are currently evaluating 177Lu-PSMA-617 in a dose-escalation study to determine the highest tolerable dose of the drug in patients with progressive mCRPC. So far, the phase I trial has not shown any significant acute or dose-limiting toxicities, says Tagawa. The low-grade toxicities observed were dry mouth and nausea, which were seen in other the prospective phase II study from Australia.
 
Tagawa says that overall, about 70% of patients on this trial had declines in their PSMA. Approximately 45% had at least a 50% decline in their PSMA. Control or decline was also observed in circulating tumor cell counts compared to baseline at 12 weeks. The data for progression-free and overall survival are not mature, Tagawa notes.

Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.